Does the media refer more to ENTA or CGTX?

In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Enanta Pharmaceuticals' score of 0.21 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGTX or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% Palisade Bio N/A -33.47% -31.79%

Does the media refer more to CGTX or PALI?

In the previous week, Palisade Bio had 8 more articles in the media than Cognition Therapeutics. MarketBeat recorded 9 mentions for Palisade Bio and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Palisade Bio's score of -0.21 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, CGTX or IKT?

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A

Is CGTX or IKT more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% Inhibikase Therapeutics N/A -42.80% -40.58%

Does the media favor VNDA or CGTX?

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 1 mentions for Cognition Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 0.84 beat Cognition Therapeutics' score of 0.79 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGTX or AMRN?

In the previous week, Amarin had 6 more articles in the media than Cognition Therapeutics. MarketBeat recorded 7 mentions for Amarin and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Amarin's score of -0.29 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cognition Therapeutics (CGTX) Competitors

$0.98 -0.01 (-1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 +0.02 (+2.08%)

As of 07:09 PM Eastern

Compare

CGTX vs. ENTA, PALI, IKT, VNDA, and AMRN

Should you buy Cognition Therapeutics stock or one of its competitors? Cognition Therapeutics's main competitors and comparable companies include Enanta Pharmaceuticals (ENTA), Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), and Amarin (AMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cognition Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cognition Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.29	-$81.89M	-$2.41	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Enanta Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

Cognition Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Cognition Therapeutics' return on equity of -50.17% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Cognition Therapeutics	N/A	-50.17%	-40.22%

In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Enanta Pharmaceuticals' score of 0.21 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enanta Pharmaceuticals presently has a consensus target price of $19.50, indicating a potential upside of 38.30%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 238.58%. Given Cognition Therapeutics' higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Palisade Bio?

Cognition Therapeutics (NASDAQ:CGTX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Palisade Bio has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Palisade Bio	$500K	700.57	-$16.78M	-$0.48	N/A

Cognition Therapeutics currently has a consensus price target of $3.33, indicating a potential upside of 238.58%. Palisade Bio has a consensus price target of $9.00, indicating a potential upside of 347.76%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio's return on equity of -33.47% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Palisade Bio	N/A	-33.47%	-31.79%

In the previous week, Palisade Bio had 8 more articles in the media than Cognition Therapeutics. MarketBeat recorded 9 mentions for Palisade Bio and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Palisade Bio's score of -0.21 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cognition Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Palisade Bio beats Cognition Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Inhibikase Therapeutics' return on equity of -42.80% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

In the previous week, Cognition Therapeutics had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 1 mentions for Cognition Therapeutics and 0 mentions for Inhibikase Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Inhibikase Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Inhibikase Therapeutics	Neutral

Cognition Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cognition Therapeutics presently has a consensus price target of $3.33, suggesting a potential upside of 238.58%. Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Given Cognition Therapeutics' higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Cognition Therapeutics beats Inhibikase Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Vanda Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

Cognition Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Cognition Therapeutics	N/A	-50.17%	-40.22%

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 1 mentions for Cognition Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 0.84 beat Cognition Therapeutics' score of 0.79 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vanda Pharmaceuticals presently has a consensus price target of $13.70, suggesting a potential upside of 157.04%. Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 238.58%. Given Cognition Therapeutics' higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cognition Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.49	-$220.47M	-$4.63	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vanda Pharmaceuticals beats Cognition Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Amarin?

Cognition Therapeutics (NASDAQ:CGTX) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Amarin had 6 more articles in the media than Cognition Therapeutics. MarketBeat recorded 7 mentions for Amarin and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Amarin's score of -0.29 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cognition Therapeutics has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Amarin	$186.23M	1.57	-$38.80M	-$0.99	N/A

Cognition Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Amarin	-14.56%	-0.20%	-0.14%

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cognition Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, Amarin has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Cognition Therapeutics currently has a consensus target price of $3.33, suggesting a potential upside of 238.58%. Amarin has a consensus target price of $13.00, suggesting a potential downside of 6.07%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cognition Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Summary

Cognition Therapeutics beats Amarin on 11 of the 15 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$93.62M	$12.42B	$7.29B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	-5.79	780.42	271.38	24.10
Price / Sales	N/A	785.30	638.95	90.12
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	2.52	10.42	11.18	6.40
Net Income	-$23.49M	$2.79B	$3.46B	$348.28M
7 Day Performance	-3.48%	2.25%	1.98%	0.91%
1 Month Performance	7.07%	4.72%	7.32%	5.10%
1 Year Performance	-64.96%	7.07%	24.76%	16.16%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	2.7946 of 5 stars	$0.98 -1.1%	$3.33 +238.6%	-64.6%	$93.62M	N/A	N/A	20
ENTA Enanta Pharmaceuticals	1.6198 of 5 stars	$13.16 -2.1%	$19.50 +48.2%	+52.5%	$383.29M	$65.32M	N/A	160	Analyst Downgrade
PALI Palisade Bio	2.63 of 5 stars	$2.14 -0.5%	$9.00 +320.6%	+178.5%	$372.94M	$250K	N/A	10
IKT Inhibikase Therapeutics	1.5268 of 5 stars	$2.41 flat	$5.40 +124.1%	N/A	$336.28M	$260K	N/A	6
VNDA Vanda Pharmaceuticals	3.1114 of 5 stars	$5.22 +3.8%	$13.70 +162.5%	+11.2%	$315.62M	$215.72M	N/A	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. ENTA, PALI, IKT, VNDA, and AMRN

How does Cognition Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Cognition Therapeutics compare to Palisade Bio?

Summary

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Summary

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Cognition Therapeutics compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. ENTA, PALI, IKT, VNDA, and AMRN

How does Cognition Therapeutics compare to Enanta Pharmaceuticals?

Do institutionals & insiders believe in ENTA or CGTX?

Which has better earnings & valuation, ENTA or CGTX?

Which has more risk & volatility, ENTA or CGTX?

Is ENTA or CGTX more profitable?

Does the media refer more to ENTA or CGTX?

Do analysts prefer ENTA or CGTX?

Summary

How does Cognition Therapeutics compare to Palisade Bio?

Which has preferable valuation & earnings, CGTX or PALI?

Do analysts prefer CGTX or PALI?

Is CGTX or PALI more profitable?

Does the media refer more to CGTX or PALI?

Which has more volatility & risk, CGTX or PALI?

Do institutionals and insiders believe in CGTX or PALI?

Summary

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Is CGTX or IKT more profitable?

Does the media refer more to CGTX or IKT?

Which has more volatility and risk, CGTX or IKT?

Which has stronger valuation & earnings, CGTX or IKT?

Do institutionals & insiders hold more shares of CGTX or IKT?

Do analysts prefer CGTX or IKT?

Summary

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Which has more risk & volatility, VNDA or CGTX?

Is VNDA or CGTX more profitable?

Does the media favor VNDA or CGTX?

Do analysts prefer VNDA or CGTX?

Which has preferable valuation and earnings, VNDA or CGTX?

Do insiders & institutionals believe in VNDA or CGTX?

Summary

How does Cognition Therapeutics compare to Amarin?

Does the media refer more to CGTX or AMRN?

Which has better earnings & valuation, CGTX or AMRN?

Is CGTX or AMRN more profitable?

Do institutionals & insiders hold more shares of CGTX or AMRN?

Which has more risk & volatility, CGTX or AMRN?

Do analysts prefer CGTX or AMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools